{"name":"OptiNose","slug":"optinose","ticker":"OPTN","exchange":"NASDAQ","domain":"optinose.com","description":"OptiNose is a specialty pharmaceutical company focused on developing innovative treatments for respiratory and allergy diseases. The company's key products include Xaracoll, a nasal spray for allergic rhinitis, and Spirovant, a nasal spray for chronic rhinosinusitis with nasal polyps. OptiNose has a strong market position in the respiratory and allergy therapeutic areas.","hq":"Yardley, PA","founded":0,"employees":"N/A","ceo":"Ramy Mahmoud","sector":"Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":152000000,"revenueGrowth":10.2,"grossMargin":0,"rdSpend":3855000,"netIncome":-21541000,"cash":128785000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Xaracoll patent cliff ($15.1M at risk)","drug":"Xaracoll","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Spirovant patent cliff ($10.5M at risk)","drug":"Spirovant","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OPN-375","genericName":"OPN-375","slug":"opn-375","indication":"Gastroparesis (diabetic and idiopathic)","status":"phase_3"}]}],"pipeline":[{"name":"OPN-375","genericName":"OPN-375","slug":"opn-375","phase":"phase_3","mechanism":"OPN-375 is a selective serotonin 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying.","indications":["Gastroparesis (diabetic and idiopathic)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"OptiNose Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"OptiNose reported fourth quarter and full year 2023 financial results, with revenue of $23.4 million and a net loss of $22.3 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"OptiNose Announces Collaboration with AstraZeneca to Develop New Respiratory Treatments","summary":"OptiNose announced a collaboration with AstraZeneca to develop new treatments for respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iODQ1WWxZajF6eWdramdJRy1uNC05YjVzVjBRNVZQWGFGR0Z6STdQY1lwSkhWYzliUXlvUGVNOXBGYVdUb05oMEM5aEMzMF91Y0M4VlJuNXhCMnNHRHVNNV9wZmhjdWZ3eTlBSi01QU9PQ2IxSUtEN3JTc2w?oc=5","date":"2025-03-21","type":"deal","source":"Yahoo Finance","summary":"OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek - Yahoo Finance","headline":"OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQUnFSbjVZdnhyMmlYNG1xcl83YVkyazZxcEVRMnZ2QjRIT2M2WkJPb0dRX2ZHc19Wcl9EYmRHNV90b3pVc2d2eTdXVi1Od0x6YmRUUzZuQlVpQXBKcFNUVGxyeEJyNHpCNzRISi1DMVYzR3AzTF90YTNRX0VuN29SdFRvWQ?oc=5","date":"2025-03-20","type":"deal","source":"The Pharma Letter","summary":"Paratek to buy Optinose for up to $330 million - The Pharma Letter","headline":"Paratek to buy Optinose for up to $330 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPVHdycG0yd3ZLVWdxeDVfa1czYndhVWZSTVlJVHNNTmZpa1hacm85OWpBS29xOUVLdFVIQjBRcVU1bF9hMjBpbWtSMFJHNnBlQzhERjViYmt2R2tESnJGTm9sQ04wUnF1SE9WU1B1ZjZwXzh0VFdMQnhPd05KOFljRWhsTWttVnN5d1lsUjFpcGJpeWVZc0l5R01CTnNwZ2RpOG1fN3dGcWVFblN6MGc?oc=5","date":"2025-03-20","type":"deal","source":"The Business Journals","summary":"Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal - The Business Journals","headline":"Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPVVhoS0tXOFQ1YnkwWkhXYklxTUVjbGtNLVIydGljM3VyYkltTW90a2FraHFqbGVRbkR0R0UzWEJkSlU2S1p6ZTVXM2xZR3c2UXBSOWI4U3o2emF6UjJ5UzFHT0hqT3g0M2lBZ0tVX3NDT0NqRTlPbktvc0pkMGhsUFl3d0J3ekJ1aWt5ekQtWHRoMkRvYjVtRDRpMFM?oc=5","date":"2024-10-07","type":"pipeline","source":"citybiz","summary":"Optinose Appoints Terry Kohler as Chief Financial Officer - citybiz","headline":"Optinose Appoints Terry Kohler as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQUUJIVWxCcFpvZXAwTm1VY2NLZC12NmxLLVBNOTVNaFpoZ0xmTkl3N1RtU1Zyelh1SDlGaEpNeGVxWDJaVDJRTUJyOTlxTHd4V1Uxd0lfOTNLYTIydVhGUFcxT2hVbWl4UjNzSE43VHd1WFd6OVQ0V3pocGdIZ3NfbnE2OUhtTlZsTl84Vlh3WkRzNU10VWlCU2xuZw?oc=5","date":"2024-07-02","type":"pipeline","source":"InvestorPlace","summary":"7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million - InvestorPlace","headline":"7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQVDRSREg0U3k2SkFqT3lkc1JnaE5RRV9lUE9rc1RnTFdDYWs0Mm1FNnQ1NUVEODdkS0RFc0lBa192YzctWVpxUlZtOV9ackJ6WXUtRWRNT1NQZDVNTlBoVUc4TWJUa1pKcDZmZElKcDY2ZUFwYnpDS29FcGdfR1lqUW5aUFZ1c1ZXal9XS1MwT3VOVE00bml0cg?oc=5","date":"2023-12-07","type":"pipeline","source":"SEC.gov","summary":"Document - SEC.gov","headline":"Document","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOOW9vZFZSRk1KdWR2dkdGeFBZa2pBR2VpWUp5VWJISUhYWVV6MmxoVDFCeDhVVXp1bndWQktJZmt0dUpKYkNscHA5eXdXU1o5bkZwT1pMbk81TWNYbzlXbklzbkRxaFNpVUFOMzhSalRmemhiZkN1dGgxYnNNaXcwcUJ3dzRzU3NVUVlIY3Nfd1VfLVU2bGVwd1N3NEg?oc=5","date":"2022-12-15","type":"pipeline","source":"citybiz","summary":"Optinose Appoints Paul Spence as Chief Commercial Officer - citybiz","headline":"Optinose Appoints Paul Spence as Chief Commercial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOYUdUU1E1U25oRDNlRlgwR21UMmJqblJ2Yk03Wno2QXJXSzNNRU1IdEZWY3lVc0JaUGlCZ1lpQTZvb3dVVnZFbVU0VDlMY21LSC1LVXdGZEZxdnZnLVFyd0lYa2w0TUN0aWhPU1Q5X2N3N1FaTkxHZkRuZnllNUhQd1ZfTTl4ZXJOQllYRUFQRkdnWHlObUo5elB2aw?oc=5","date":"2022-12-09","type":"pipeline","source":"citybiz","summary":"Optinose Chief Financial Officer Michele Janis to Retire - citybiz","headline":"Optinose Chief Financial Officer Michele Janis to Retire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQdVRySFFZalQ3bng3RTVTakZkRWFpanNKTms4MENEYk84endRSG11bTJXQnljX0NIWUNXOW9RcXQ3NFMwYk1PWVhlMFNPaWxnRGVNM1dIbjNRVW9ydUp3RFNTRFRtM3VjcnNjQjVBaWU4WDF3dWZIaUM3Rk9mV29lX2JRRGYxQUd6azNVV2RpYk9oYjZEejNXWnNWMDlsdnB6MVRFMHJsQVlzdnVRZlVxOGdvcWZhSjZVWnpPU2gzNHB0MTkwbFFBckxZM1VQNzJhNHVsa1d4QTMyWWFZRkJqQjh4X084Q2N2RTF1MlFMa2lwTEluNXNVMzc3YVlucXB4amhHZXo3YlQ4SktNZ0pUSTdERQ?oc=5","date":"2021-04-27","type":"pipeline","source":"BioSpace","summary":"New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day - BioSpace","headline":"New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Conges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1rQ2pLTlJVeXp5dWZqYnR1cVh5LUw2QXVhRk9IVGF5ajgtUDBzVFhtR0JCUE1zSk5SUjN3VFVfeV9SemJRemNYckNOcTlySWRrSE1jMHRIRGJGZw?oc=5","date":"2017-11-01","type":"pipeline","source":"MarketBeat","summary":"OptiNose (OPTN) Stock Price, News & Analysis - MarketBeat","headline":"OptiNose (OPTN) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Xaracoll","drugSlug":"fluticasone-propionate","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":15100000},{"drugName":"Spirovant","drugSlug":"cilioretinal-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10500000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","AstraZeneca","GlaxoSmithKline"],"therapeuticFocus":["Respiratory","Allergy"],"financials":{"source":"sec_edgar+yahoo","revenue":78226000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":78226000,"period":"2024-12-31"},{"value":70987000,"period":"2023-12-31"},{"value":70987000,"period":"2023-12-31"},{"value":76276000,"period":"2022-12-31"},{"value":76276000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":3855000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21541000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":128785000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}